Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 25, 2023

SELL
$1.22 - $4.83 $1,069 - $4,235
-877 Reduced 52.93%
780 $0
Q2 2023

Jul 28, 2023

SELL
$2.95 - $4.44 $2,368 - $3,565
-803 Reduced 32.64%
1,657 $6,000
Q1 2023

Apr 26, 2023

BUY
$2.94 - $4.18 $3,257 - $4,631
1,108 Added 81.95%
2,460 $8,000
Q4 2022

Jan 24, 2023

BUY
$2.73 - $3.7 $1,717 - $2,327
629 Added 87.0%
1,352 $0
Q3 2022

Nov 10, 2022

BUY
$0.48 - $3.48 $196 - $1,423
409 Added 130.25%
723 $2,000
Q2 2022

Aug 01, 2022

SELL
$2.22 - $4.54 $3,214 - $6,573
-1,448 Reduced 82.18%
314 $1,000
Q1 2022

Apr 21, 2022

SELL
$3.58 - $4.98 $1,156 - $1,608
-323 Reduced 15.49%
1,762 $7,000
Q4 2021

Jan 18, 2022

BUY
$4.17 - $7.09 $708 - $1,205
170 Added 8.88%
2,085 $10,000
Q3 2021

Nov 05, 2021

BUY
$5.87 - $7.85 $2,794 - $3,736
476 Added 33.08%
1,915 $12,000
Q3 2020

Nov 03, 2020

SELL
$11.33 - $19.81 $1,042 - $1,822
-92 Reduced 6.01%
1,439 $27,000
Q2 2020

Jul 27, 2020

BUY
$4.2 - $15.45 $953 - $3,507
227 Added 17.41%
1,531 $17,000
Q1 2020

Apr 22, 2020

BUY
$3.38 - $10.63 $4,407 - $13,861
1,304 New
1,304 $6,000

Others Institutions Holding MESO

About MESOBLAST LTD


  • Ticker MESO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 147,316,000
  • Market Cap $1.57B
  • Description
  • Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its ...
More about MESO
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.